KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Long-Term Investments (2017 - 2025)

Moderna (MRNA) has disclosed Long-Term Investments for 9 consecutive years, with $2.3 billion as the latest value for Q4 2025.

  • Quarterly Long-Term Investments fell 6.34% to $2.3 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.3 billion through Dec 2025, down 6.34% year-over-year, with the annual reading at $2.3 billion for FY2025, 6.34% down from the prior year.
  • Long-Term Investments for Q4 2025 was $2.3 billion at Moderna, up from $2.1 billion in the prior quarter.
  • The five-year high for Long-Term Investments was $10.2 billion in Q2 2022, with the low at $36.0 million in Q1 2023.
  • Average Long-Term Investments over 5 years is $4.5 billion, with a median of $3.9 billion recorded in 2021.
  • The sharpest move saw Long-Term Investments tumbled 99.61% in 2023, then skyrocketed 10005.56% in 2024.
  • Over 5 years, Long-Term Investments stood at $6.8 billion in 2021, then grew by 21.55% to $8.3 billion in 2022, then crashed by 43.77% to $4.7 billion in 2023, then tumbled by 46.68% to $2.5 billion in 2024, then decreased by 6.34% to $2.3 billion in 2025.
  • According to Business Quant data, Long-Term Investments over the past three periods came in at $2.3 billion, $2.1 billion, and $2.4 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.